Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Carbetocin (Duratocin) vs Linaclotide (Linzess)
An educational, source-based comparison of Carbetocin (Duratocin) and Linaclotide (Linzess) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting oxytocin analog for postpartum hemorrhage prevention.
Synthetic, heat-stable oxytocin analog with longer half-life. Stimulates uterine contraction following delivery to prevent postpartum hemorrhage.
- Postpartum hemorrhage prevention (C-section, vaginal delivery)
- • FDA-approved (also widely used internationally).
- • Single-dose use only.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Carbetocin (Duratocin) | WHO CHAMPION trial | NEJM | 2018 | Heat-stable carbetocin non-inferior to oxytocin for PPH prevention. |
| Linaclotide (Linzess) | Linaclotide phase 3 trials | NEJM | 2011 | Improved abdominal pain and bowel function in IBS-C. |
Side-effect & safety grid
- FDA-approved (also widely used internationally).
- Single-dose use only.
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Carbetocin (Duratocin) vs Linaclotide (Linzess) — Key differences
- Class: Carbetocin (Duratocin) is classified as Oxytocin Analog · Obstetrics, while Linaclotide (Linzess) is GC-C Agonist · Gastrointestinal.
- Primary research focus: Carbetocin (Duratocin) — postpartum hemorrhage prevention (c-section, vaginal delivery); Linaclotide (Linzess) — ibs-c.
- Tag: FDA-Approved · Obstetrics vs FDA-Approved · GI.